Aadi Bioscience AADI

Jump To Section

    $

    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    .
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    +$0.02 (+1.19%)Past DayToday's Volume:
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0

    Relative Strength Index (RSI)

    - The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

    - The RSI is calculated using the following formula:

    RSI = 100 - (100 / (1 + RS))

    Where RS is the ratio of the average gains to the average losses over a specified period.

    - The default time period used is 14 days.

    - RSI values range between 0 and 100.

    RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

    RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

    RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

    About

    Business overview of Aadi Bioscience (AADI)
    Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. It has one operating segment, which is the business of developing and commercializing proprietary therapeutic. Geographically, it is located in the United States.

    Key Insights

    Critical company metrics and information

    • Latest Closing Price

      $2.12

    • Market Cap

      $98.13 Million

    • Price-Earnings Ratio

      -4.61

    • Total Outstanding Shares

      24.70 Million Shares

    • Total Employees

      53

    • Dividend

      No dividend

    • IPO Date

      August 27, 2021

    • SIC Description

      Pharmaceutical Preparations

    • Primary Exchange

      NASDAQ

    • Type

      Common Stock

    • Headquarters

      17383 sunset avenue, Pacific palisades, CA, 90272

    • Homepage

      https://www.aadibio.com

    Historical Stock Splits

    If you bought 1 share of AADI before August 31, 2005, you'd have 5.63 shares today.
    Execution DateSplit Amount
    December 18, 20074.5-for-1
    August 31, 20055-for-4

    Cash Flow Statement

    July 1, 2024 to September 30, 2024
    MetricValue
    Net Cash Flow, Continuing$-10.60 Million
    Net Cash Flow$-10.60 Million
    Net Cash Flow From Operating Activities$-15.69 Million
    Net Cash Flow From Investing Activities$5.08 Million
    Net Cash Flow From Financing Activities, Continuing$0
    Net Cash Flow From Operating Activities, Continuing$-15.69 Million

    Income Statement

    July 1, 2024 to September 30, 2024
    MetricValue
    Research and Development$10.00 Million
    Net Income/Loss Available To Common Stockholders, Basic$-12.55 Million
    Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0
    Diluted Earnings Per Share$-0.46
    Diluted Average Shares$27.04 Million
    Operating Expenses$19.82 Million

    Comprehensive Income

    July 1, 2024 to September 30, 2024
    MetricValue
    Comprehensive Income/Loss$-12.48 Million
    Comprehensive Income/Loss Attributable To Parent$-12.48 Million
    Other Comprehensive Income/Loss$-12.48 Million
    Comprehensive Income/Loss Attributable To Noncontrolling Interest$0

    Balance Sheet

    July 1, 2024 to September 30, 2024
    MetricValue
    Cash$62.60 Million
    Equity Attributable To Noncontrolling Interest$0
    Other Current Assets$9.25 Million
    Equity Attributable To Parent$68.87 Million
    Assets$85.70 Million
    Current Liabilities$15.81 Million

    Historical Dividends

    Announcement DatePayment DateRecord DateAmountFrequency
    No historical dividends

    Recent Headlines From The Web

    Latest news, press releases, and media coverage about AADI from trusted financial sources
      Boost your savings and earn 4.15% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
      All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

      ⓒ 2025 Financhle. All Rights Reserved.